We scan new podcasts and send you the top 5 insights daily.
Carbone says trial patients are fit, but real-world frailty or renal problems may favor less chemotherapy. He does not use age alone to withhold dual immunotherapy from patients over 80 with good performance and organ function, though interstitial lung disease or aggressive autoimmune disease may make dual immunotherapy a poor fit.
Real-world data confirms that the favorable safety profile of CAR T-cell therapies like Obicell holds true in broad clinical practice. This has been a crucial factor in expanding eligibility to older patients, with successful treatments now being administered to individuals in their 70s and 80s.
For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."
Carbone points to Keynote 407 five-year data where PD-L1-negative squamous tumors did so poorly that more control-arm patients were alive than treated patients. In his practice, he uses the 9LA dual immunotherapy regimen in that setting for those patients because long-term survival with chemoimmunotherapy is unimpressive.
Unlike stem cell transplants, CAR T-cell therapy has less intense conditioning, making it a viable option for patients into their late 80s. Eligibility focuses more on fitness and frailty rather than chronological age, broadening access for a larger patient population.
For frail elderly patients, it's crucial to discern if poor performance status stems from disease or comorbidities. A practical approach is to initiate treatment with biologic agents alone. If the patient's status improves, it confirms the cancer is the cause, justifying the subsequent, careful addition of cytotoxic chemotherapy.
Unlike autologous transplant, CAR T-cell therapy does not have strict age or organ function cutoffs. Patients over 75, or with conditions like an ejection fraction of 40%, can be eligible. The key pre-treatment goal is disease stability, not a deep response, making it accessible to a wider, less fit patient population.
Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.
Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.
Even in elderly or frail patients with MSI-high endometrial cancer, the rapid and effective tumor response from combination chemotherapy and immunotherapy often improves quality of life so significantly that it's the preferred approach over single-agent IO.
Chronological age alone should not disqualify older patients from CAR T therapy. Experts successfully treat fit, motivated octogenarians with Siltacel, emphasizing that performance status, motivation, and disease control are more critical factors than age.